DUBLIN--(BUSINESS WIRE)--The "Tuberculosis Pipeline Highlights - 2017 Update" drug pipelines has been added to ResearchAndMarkets.com's offering.
Tuberculosis Pipeline Highlights - 2017 Update, provides most up-to-date information on key pipeline products in the global Tuberculosis market.
It covers emerging therapies for Tuberculosis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides Tuberculosis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Tuberculosis pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
Company:
The report provides Tuberculosis pipeline products by the company.
Short-term Launch Highlights:
Find out which Tuberculosis pipeline products will be launched in the US and Ex-US till 2020.
Summary:
- Tuberculosis phase 3 clinical trial pipeline products
- Tuberculosis phase 2 clinical trial pipeline products
- Tuberculosis phase 1 clinical trial pipeline products
- Tuberculosis preclinical research pipeline products
- Tuberculosis discovery stage pipeline products
- Tuberculosis pipeline products short-term launch highlights
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/k6l9vh/2017_tuberculosis?w=4
